Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Macular Degeneration × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 337 Brain Neoplasms 335 Glioma 202 Gliosarcoma 133 Astrocytoma 122 Neuroblastoma 109 Central Nervous System Neoplasms 107 Oligodendroglioma 74 Medulloblastoma 50 Neoplasms 49 Breast Neoplasms 46 Ependymoma 39 Melanoma 38 Carcinoma, Non-Small-Cell Lung 35 Recurrence 33 Meningioma 30 Sarcoma 28 Rhabdomyosarcoma 28 Neurofibromatosis 1 28 Osteosarcoma 27 Neoplasm Metastasis 24 Lymphoma, Non-Hodgkin 24 Lung Neoplasms 24 Wilms Tumor 23 Neuroectodermal Tumors, Primitive, Peripheral 22 Lymphoma 22 Sarcoma, Ewing 20 Rhabdoid Tumor 16 Diffuse Intrinsic Pontine Glioma 16 Ovarian Neoplasms 15

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡